Paris, July 31, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, announces the signature of an Asset Transfer and Licensing agreement covering a development and commercialisation collaboration agreement with CMS Medical Limited as well as an investment agreement with CMS Medical Venture Investment Limited, a wholly owned subsidiary of China Medical System Holdings Limited (“CMS”; HKSE:0867), and A&B (HK).
Under the terms of the agreements, Acticor Biotech will collaborate with CMS, who will have the full rights in China and certain other Asian countries (excluding Japan and India), to enable the development and commercialisation of the Company’s pipeline of drug candidates in the region. The parties will coordinate and share data from their respective clinical studies and Acticor Biotech will benefit from the investment of CMS in developing the Company’s assets in China. Acticor Biotech will also receive commercial milestones and royalties based on the achievement of sales milestones by CMS and make a manufacturing margin on any product the Company supplies.
Gilles Avenard, Chief Executive Officer of Acticor Biotech, commented: “We are pleased to have signed this development and commercialisation agreement with China Medical System Holdings Limited. As a specialty pharmaceutical company based in China, CMS is the ideal strategic partner to help us advance our platform and commercialise potential products in this important region. We look forward to working closely with CMS”
Mr. Lam Kong, Chairman, Chief Executive and President of CMS, added: “I am excited by this opportunity to work with the Acticor biotech team to drive forward the development of the Company’s drug candidate. I believe ACT017, Acticor Biotech’s drug candidate offers great potential as a novel approach to improve management of acute phase of vascular diseases, where there is a recognised unmet need for new effective treatment options.”
Agile Capital Markets acted as a financial advisor for Acticor Biotech.
About China Medical System Holdings Limited
CMS is a specialty pharmaceutical company based in China, engaging in marketing, promotion and sales of prescription drugs and other medicinal products to all therapeutic departments in hospitals nation-wide. CMS builds up its product portfolio for its target markets by asset acquisition, equity investment and licensing-in on the global basis as well as in-house R&D. It is listed on the Hong Kong Stock Exchange (867.HK) with a market capitalisation of approximately HK$33.4 billion (c. €3.6 billion) as at July 31 2018.
About ACT017, the Therapeutic Candidate
Acticor is developing ACT017, a humanized Antibody Fragment (Fab). The therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of antithrombotic efficacy of ACT017 and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological haemostasis. This limits the bleeding risk associated with its inhibition. https://acticor-biotech.com/technology/
About Acticor Biotech
Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. Acticor Biotech is built upon the expertise and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University.
For more information, go to: https://acticor-biotech.com/
Chief Executive Officer
Media – NewCap:
+33(0) 1 44 71 00 12 / +33(0) 6 88 20 35 59
Read next in 'Press Releases'
- Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS
- Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke
- ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120
- ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M
- ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS